BIOXODES
- Biotech or pharma, therapeutic R&D
Bioxodes is a clinical-stage biotech company developing first-in-class therapies to prevent and treat thrombotic and inflammatory diseases. Our lead candidate BIOX-101 – derived from a protein in the saliva of the tick – is designed to mitigate the secondary neuroinflammatory effects of haemorrhagic stroke, a high unmet medical need. Bioxodes is currently in a Series B.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}